Ambrx Biopharma Net Worth 2020-2022 | AMAM
Interactive chart of historical net worth (market cap) for Ambrx Biopharma (AMAM) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Ambrx Biopharma net worth as of January 25, 2023 is $0.08B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.083B | $0.007B |
| Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $155.571B | 9.49 |
| GSK (GSK) | United Kingdom | $71.996B | 8.97 |
| Bio-Rad Laboratories (BIO.B) | United States | $12.069B | 28.64 |
| QIAGEN (QGEN) | Netherlands | $11.433B | 19.52 |
| Ginkgo Bioworks Holdings (DNA) | United States | $3.414B | 0.00 |
| Myovant Sciences (MYOV) | United Kingdom | $2.604B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.676B | 25.16 |
| Biohaven (BHVN) | United States | $1.305B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $0.671B | 5.28 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.359B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.073B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.028B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.024B | 0.00 |
